MY170725A - Dengue-virus serotype neutralizing antibodies - Google Patents

Dengue-virus serotype neutralizing antibodies

Info

Publication number
MY170725A
MY170725A MYPI2014700529A MYPI2014700529A MY170725A MY 170725 A MY170725 A MY 170725A MY PI2014700529 A MYPI2014700529 A MY PI2014700529A MY PI2014700529 A MYPI2014700529 A MY PI2014700529A MY 170725 A MY170725 A MY 170725A
Authority
MY
Malaysia
Prior art keywords
dengue
neutralizing antibodies
virus serotype
virus
serotype neutralizing
Prior art date
Application number
MYPI2014700529A
Inventor
Chayanee Setthapramote
Tadahiro Sasaki
Motoki Kuhara
Pongrama Ramasoota
Aree Thattiyaphong
Surapee Anantapreecha
Pathom Sawanpanyalert
Yoshinobu Okuno
Kazuyoshi Ikuta
Atchareeya A-Nuegoonpipat
Panadda Dhepakson
Apichai Prachasuphap
Pattarin Prawatsilpa
Original Assignee
Univ Osaka
Univ Osaka Res Found For Microbial Diseases
Medical & Biol Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Univ Osaka Res Found For Microbial Diseases, Medical & Biol Lab Co Ltd filed Critical Univ Osaka
Publication of MY170725A publication Critical patent/MY170725A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Materials and methods are provided for treating dengue infections. Human monoclonal antibodies against all serotypes of dengue virus are also provided. Methods of using human monoclonal antibodies to neutralize all dengue?virus serotypes are provided using patients' peripheral blood lymphocytes. Fig. 1
MYPI2014700529A 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies MY170725A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532605P 2011-09-09 2011-09-09
US201161532671P 2011-09-09 2011-09-09

Publications (1)

Publication Number Publication Date
MY170725A true MY170725A (en) 2019-08-27

Family

ID=47116163

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014700529A MY170725A (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies

Country Status (4)

Country Link
AU (1) AU2012305807B2 (en)
MY (1) MY170725A (en)
SG (1) SG11201400100SA (en)
WO (1) WO2013035345A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015122995A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
CN105004860B (en) * 2015-07-24 2016-09-21 鲁东大学 Florfenicol quick detection kit and preparation, using method
CN105137068B (en) * 2015-07-24 2017-03-01 鲁东大学 Florfenicol Site Detection reagent paper and its preparation, using method
JP7155009B2 (en) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド Preparation of antibody molecules against dengue virus
CN109929033B (en) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 Human antibody specifically binding to four serotype dengue viruses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
DK0669836T3 (en) 1992-11-13 1996-10-14 Idec Pharma Corp Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
DE4337197C1 (en) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Process for the selective preparation of hybridoma cell lines which produce monoclonal antibodies with high cytotoxicity against human CD16 antigen, and the preparation of bispecific monoclonal antibodies using such monoclonal antibodies and the CD30-HRS-3 antibody for therapy of human tumours
EP0985033A4 (en) 1997-04-04 2005-07-13 Biosite Inc Polyvalent and polyclonal libraries
WO2004076677A2 (en) * 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2007119808A1 (en) * 2006-04-13 2007-10-25 Medical And Biological Laboratories Co., Ltd. Fusion partner cells
US8337854B2 (en) * 2007-04-04 2012-12-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in Fc region
NZ592054A (en) * 2008-10-13 2013-06-28 Inst Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
EP2380976A4 (en) * 2008-12-25 2012-11-07 Univ Osaka Human anti-human influenza virus antibody
SG173482A1 (en) * 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections

Also Published As

Publication number Publication date
SG11201400100SA (en) 2014-06-27
AU2012305807A1 (en) 2014-02-20
AU2012305807B2 (en) 2015-08-20
AU2012305807A8 (en) 2014-03-13
WO2013035345A2 (en) 2013-03-14
WO2013035345A3 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
CY1123739T1 (en) ANTI-CD38 ANTIBODIES
PH12017501075B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
EA201300016A1 (en) HUMAN ANTIBODY CONJUGATES AGAINST TISSUE FACTOR WITH DRUGS
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
EA032929B1 (en) Human immunodeficiency virus neutralizing antibody and methods of use thereof
UA112288C2 (en) Antibody forvulation and therapeutic regimens
MX2012001882A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use.
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
IN2014DN07149A (en)
EP2558493A4 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
UA109658C2 (en) ANTIBODY AGAINST CGRP
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
DE602007013618D1 (en) ANTIBODIES TO THE HUMAN CYTOMEGALIE VIRUS (HCMV)
MY170725A (en) Dengue-virus serotype neutralizing antibodies
BR112013032456A2 (en) anti-cxcr4 antibody with effector functions and its use for cancer treatment
MX2015008534A (en) ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF.
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
MX356745B (en) A human monoclonal antibody against the vp1 protein of jc virus.
EA201390417A1 (en) ANTI-DIABETIC SOLID PHARMACEUTICAL COMPOSITIONS
MX2013010367A (en) Compositions and methods for the therapy and diagnosis of influenza.
EA201390117A1 (en) COMPOSITION OF ANTIBODIES TO VEGFR-3
MX2013009529A (en) Treatment of fistulizing crohn's disease.
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer